Tocilizumab in the management of posttransfusion hyperhemolysis syndrome in sickle cell disease: The experience so far.

Even though the number of cases of posttransfusion hyper hemolysis syndrome treated with Tocilizumab are few, they have all been associated with rapid clinical responses with no observed adverse events suggesting that the role of Tocilizumab in this context needs to be further explored.